Silence Therapeutics Cash Flow Statement (2024-2026) | SLN

Cash Flow Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter) -2.31M-19.75M-35.54M24.26M-28.53M-27.35M-20.96M-11.77M-14.96M
Depreciation and Depletion (Quarter) 0.09M0.09M0.09M0.08M0.07M0.08M0.08M0.08M0.07M
Share-based Compensation (Quarter) 4.12M4.14M4.07M3.98M3.54M2.08M2.54M-0.09M2.45M
Deferred Taxes (Quarter) 0.24M0.23M0.05M0.32M0.01M0.00M
Cash from Operations (Quarter) -9.14M-5.41M-25.61M-27.48M-12.31M-21.79M-10.88M-17.32M-15.60M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter) 0.06M0.06M0.07M0.06M0.07M0.07M0.07M0.04M0.03M
Depreciation & Amortization (CF) (Quarter) 0.09M0.09M0.09M0.08M0.07M0.08M0.08M0.08M0.07M
Change in Working Capital
Change in Receivables (Quarter) 10.01M-7.97M-1.75M0.61M-0.94M0.01M-0.06M-0.03M
Other Working Capital Changes (Quarter) 0.77M1.87M-0.92M-0.39M0.59M-3.02M-5.33M1.74M-0.93M
Investing Activities
Capital Expenditures (Quarter) 0.09M-0.64M0.77M0.00M-0.02M0.07M
Cash from Investing Activities (Quarter) -49.91M-0.04M-38.14M66.12M-44.38M-1.56M51.29M-53.34M10.00M
Financing Activities
Cash from Financing Activities (Quarter) 133.02M1.19M7.97M-0.10M0.01M0.00M
Change in Capital Stock
Net Equity Issued and Repurchased (Quarter) 133.02M1.19M7.97M-0.10M0.01M0.00M
Additional items
Exchange Rate Effect (Quarter) -0.04M-0.01M0.27M-0.16M0.23M0.20M-0.11M-0.13M-0.02M
Change in Cash (Quarter) 73.97M-4.26M-55.77M38.55M-56.68M-23.34M40.40M-70.62M-5.60M
Free Cash Flow (Quarter) -9.14M-5.49M-24.96M-28.25M-12.31M-21.77M-10.95M-17.32M-15.60M
Net Cash Flow (Quarter) 73.97M-4.26M-55.77M38.55M-56.68M-23.35M40.41M-70.65M-5.60M